|
Patent landscape, scope, and claims: |
United States Drug Patent 10,119,143: Scope, Claims, and Landscape Analysis
What is the Core Subject Matter of U.S. Patent 10,119,143?
United States Patent 10,119,143, titled "Methods for treating a disease with an antibody that inhibits PD-1," claims methods for treating various cancers using an antibody that blocks the programmed death-1 (PD-1) receptor. The patent focuses on specific patient populations and therapeutic regimens, aiming to enhance the efficacy of such antibody treatments. The claims define novel methods of administration and patient selection that differentiate from prior art, primarily targeting the enhancement of anti-tumor immune responses.
What are the Key Claims and Scope of the Patent?
The patent's primary claims are directed towards methods of treating specific diseases, including but not limited to melanoma, lung cancer (non-small cell lung cancer), renal cell carcinoma, and urothelial carcinoma. A core aspect of the claims is the administration of an antibody that inhibits PD-1, or a fragment thereof, to a subject.
Specifically, the claims define methods that encompass:
- Patient Selection Criteria: Claims often specify patient populations defined by certain biological markers, such as the absence of specific gene mutations or the presence of particular immune cell infiltrations. For example, claim 1 specifies "wherein the subject has a tumor that does not have a mutation in a gene selected from the group consisting of KRAS, EGFR, BRAF, and PIK3CA." This focus on non-mutated tumors represents a strategic attempt to define a patient group likely to respond to PD-1 inhibition, differentiating from broader patient populations previously targeted.
- Dosage and Administration Regimens: The patent details specific dosage ranges and schedules for administering the PD-1 inhibiting antibody. Claim 1, for instance, describes administering "an effective amount of an anti-PD-1 antibody" at specific intervals. The precise timing and quantity are critical to the claimed method.
- Combination Therapies: Some claims may also cover combination therapies, where the PD-1 inhibitor is administered alongside other therapeutic agents, such as chemotherapy or other immunotherapies. While this patent primarily focuses on monotherapy with PD-1 inhibitors, the claims are drafted to potentially encompass synergistic approaches.
- Method of Enhancing Immune Response: A significant portion of the patent's innovation lies in the method of enhancing an anti-tumor immune response. The claims outline how the administration of the antibody leads to increased T-cell activity and infiltration into tumor sites.
Table 1 summarizes key characteristics of representative claims within U.S. Patent 10,119,143:
| Claim Element |
Description |
Specific Example (from Claim 1) |
| Therapeutic Agent |
Antibody or fragment thereof that inhibits PD-1. |
"an anti-PD-1 antibody" |
| Target Disease |
Cancerous diseases, including melanoma, lung cancer, renal cell carcinoma, and urothelial carcinoma. |
"melanoma, non-small cell lung cancer, renal cell carcinoma, or urothelial carcinoma" |
| Subject Criteria |
Specific patient characteristics to optimize treatment response. |
"wherein the subject has a tumor that does not have a mutation in a gene selected from the group consisting of KRAS, EGFR, BRAF, and PIK3CA." |
| Administration Method |
Specified dosage, frequency, and duration of antibody administration. |
"administering to the subject an effective amount of an anti-PD-1 antibody" (specific dosage and schedule detailed in other parts of the specification) |
| Therapeutic Goal |
To inhibit tumor growth and enhance an anti-tumor immune response. |
"wherein the administration enhances an anti-tumor immune response" |
| Exclusions/Differentiation |
Defining specific genetic profiles or conditions that distinguish the claimed method from prior art approaches. |
Exclusion of tumors with KRAS, EGFR, BRAF, or PIK3CA mutations. |
The scope of the patent is therefore defined by these specific claims, which delineate a particular method of medical treatment rather than the compound itself. This focus on method-of-treatment claims is common in the pharmaceutical industry, allowing for patent protection of novel therapeutic applications and patient selection strategies.
What is the Patent Landscape for PD-1 Inhibitors and Related Technologies?
The patent landscape for PD-1 inhibitors is highly competitive and densely populated. Numerous patents cover the antibodies themselves, their manufacturing processes, specific formulations, and various therapeutic uses. U.S. Patent 10,119,143 fits within this broader landscape by claiming a specific method of using such an antibody.
Key aspects of the patent landscape include:
- Composition of Matter Patents: These patents cover the specific molecular structures of PD-1 inhibiting antibodies, such as pembrolizumab (Keytruda) and nivolumab (Opdivo). Companies like Merck & Co. and Bristol Myers Squibb hold foundational patents in this area.
- Method of Treatment Patents: U.S. Patent 10,119,143 is an example of this category. These patents protect novel ways to use existing or new drugs, often by defining specific patient populations, dosage regimens, or combination therapies. The success of these patents relies on demonstrating a novel and non-obvious method that provides a tangible benefit over prior art.
- Diagnostic Patents: Patents may also cover diagnostic methods for identifying patients who are likely to respond to PD-1 therapy, such as tests for PD-L1 expression levels or tumor mutational burden (TMB).
- Manufacturing and Formulation Patents: These cover the processes used to produce the antibodies and the specific ways they are formulated for administration, ensuring stability, bioavailability, and ease of use.
- Biomarker Patents: Patents related to biomarkers that predict response or resistance to PD-1 inhibitors are also prevalent. These can include genetic mutations, protein expression levels, or specific immune cell profiles.
The patent landscape can be broadly categorized by the stage of development and the nature of the innovation:
- Early-Stage Foundational Patents: These typically cover the discovery of the PD-1 pathway, the identification of PD-1 as a target, and the initial development of antibodies that block this pathway. These patents are often held by major pharmaceutical companies and research institutions.
- Second-Generation and Niche Patents: These patents focus on improving existing therapies, such as developing antibodies with higher affinity, longer half-life, or reduced side effects. They also encompass novel therapeutic applications, combination therapies, and specific patient stratification strategies, like the method claimed in U.S. Patent 10,119,143.
- Biosimilar and Generic Competition Patents: As blockbuster PD-1 inhibitors approach patent expiry, a growing area of patent activity involves biosimilar development, which often involves navigating and potentially challenging existing patents.
Key Players and Their Patent Holdings:
- Merck & Co.: Holds extensive patents related to pembrolizumab (Keytruda), including composition of matter and methods of treatment.
- Bristol Myers Squibb: Holds foundational patents for nivolumab (Opdivo) and related therapeutic methods.
- Genentech (Roche): Has patents in the immunotherapy space, including PD-1/PD-L1 related technologies.
- Other Biotechnology Companies and Academic Institutions: Contribute a significant number of patents covering various aspects of PD-1 pathway modulation and cancer immunotherapy.
U.S. Patent 10,119,143 distinguishes itself by specifying a patient population that lacks certain common oncogenic mutations (KRAS, EGFR, BRAF, PIK3CA) in their tumors. This precise definition aims to carve out a specific and potentially more responsive subset of cancer patients for PD-1 inhibitor therapy, thereby strengthening its patentability over broader method claims. The patent seeks to protect a method of treatment that leverages specific tumor genetic profiles to predict and enhance therapeutic outcomes.
What are the Potential Implications of U.S. Patent 10,119,143 for Market Entry and Competition?
The existence and scope of U.S. Patent 10,119,143 have direct implications for market entry and competitive dynamics in the immuno-oncology space, particularly for drugs targeting the PD-1 pathway.
- Blocking New Entrants (Method of Treatment): For generic or biosimilar manufacturers, this patent represents a hurdle if they intend to market a PD-1 inhibiting antibody for the specific methods and patient populations claimed. Even if a company has developed a PD-1 antibody, they may be restricted from using it for treating patients with tumors lacking KRAS, EGFR, BRAF, and PIK3CA mutations, or for specific administration schedules, without a license.
- Licensing and Collaboration Opportunities: Companies seeking to utilize the specific therapeutic methods described in the patent would likely need to secure a license from the patent holder. This can lead to licensing agreements, collaborations, or even acquisitions, as companies aim to integrate patented methods into their drug development or commercialization strategies.
- Delineating Market Niches: The patent effectively delineates a specific niche within the broader PD-1 inhibitor market. This suggests that the patent holder may be targeting a particular sub-segment of cancer patients, potentially those who have not responded to other treatments or who have specific genetic profiles that make them ideal candidates for this particular method of PD-1 inhibition.
- Potential for Litigation: As with any valuable patent in a highly lucrative market, U.S. Patent 10,119,143 is subject to potential challenges, such as infringement lawsuits or invalidity challenges. Competitors may seek to design around the patent or argue that the claims are not valid based on prior art.
- Impact on R&D Strategies: The claims of this patent can influence the R&D strategies of other companies. Researchers may focus on developing PD-1 inhibitors that are not covered by the patent's claims, or they may seek to develop alternative therapeutic approaches that bypass the claimed method altogether. This could involve targeting different immune checkpoints, developing novel combination therapies not covered by the patent, or focusing on patient populations explicitly excluded by the claims.
- Value Proposition for the Patent Holder: For the patent holder, this patent provides a degree of market exclusivity for a specific therapeutic method. This can enhance the commercial value of their PD-1 inhibitor product or their licensing portfolio. The patent reinforces the strategic advantage of developing and patenting not just the drug molecule, but also novel ways to administer it and specific patient groups that benefit most.
The claims' specificity regarding patient genetic profiles is particularly significant. It reflects a maturation of immuno-oncology, moving beyond broad indications to more targeted therapeutic strategies. This can lead to more predictable clinical outcomes and potentially reduced healthcare costs by avoiding ineffective treatments in non-responders. However, it also necessitates sophisticated diagnostic infrastructure to identify eligible patients, influencing the go-to-market strategy for any drug utilizing this patented method.
Key Takeaways
- U.S. Patent 10,119,143 protects methods of treating specific cancers using PD-1 inhibiting antibodies, with a key differentiator being the selection of patients whose tumors lack common oncogenic mutations (KRAS, EGFR, BRAF, PIK3CA).
- The patent claims focus on specific administration regimens and the enhancement of anti-tumor immune responses within these defined patient populations.
- The patent landscape for PD-1 inhibitors is crowded, with patents covering composition of matter, methods of treatment, diagnostics, and manufacturing. This patent adds a layer of complexity by protecting a specific method of treatment rather than the antibody itself.
- Implications for market entry include potential barriers for competitors seeking to use the claimed methods, opportunities for licensing and collaboration, and the delineation of specific market niches.
- The patent's focus on genetically defined patient subgroups highlights a trend towards personalized medicine in immuno-oncology, influencing R&D strategies and requiring advanced diagnostic capabilities for clinical application.
FAQs
-
Does U.S. Patent 10,119,143 claim a new drug molecule?
No, U.S. Patent 10,119,143 does not claim a new drug molecule. It claims methods of treating diseases using an antibody that inhibits PD-1, focusing on specific patient selection criteria and administration protocols.
-
What specific cancers are covered by the patent's claims?
The patent claims are directed towards methods for treating melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma, among other cancerous diseases.
-
How does the patient selection criterion in the patent differ from general PD-1 inhibitor use?
The patent specifically claims methods for treating subjects whose tumors do not have mutations in KRAS, EGFR, BRAF, or PIK3CA. This contrasts with broader use of PD-1 inhibitors, which may be applied to patients with a wider range of genetic profiles.
-
Can a company develop a generic version of a PD-1 inhibitor if this patent is active?
A company can develop a generic or biosimilar version of a PD-1 inhibitor, but they may be restricted from using it for the specific methods and patient populations claimed by U.S. Patent 10,119,143 without obtaining a license.
-
What is the primary significance of method-of-treatment patents like U.S. Patent 10,119,143 in the pharmaceutical industry?
Method-of-treatment patents allow for the protection of novel therapeutic applications, patient stratification strategies, and optimized administration regimens, even if the underlying drug molecule is already known or patented. This provides additional market exclusivity and can drive innovation in how existing drugs are used.
Citations
[1] U.S. Patent No. 10,119,143 (filed Jan. 30, 2015).
More… ↓
⤷ Start Trial
|
